Skip to content
stoqly

Lantheus

LNTH Nasdaq Health Care Supplies Financials FY2016–FY2025

Lantheus' revenue rose 0.5% to $1.5 billion in fiscal 2025. Its operating margin was 20.2%, down from 29.8% a year earlier. Free cash flow was $354 million, down 28.2%. It paid out $300 million in dividends and buybacks, 85% of free cash flow. The diluted share count fell 4.5%.

Last close · Oct 23, 2026

$99.80

0.3%
Value it Compare
Revenue Total sales reported in the income statement.
$1.5B
0.5% vs prior year
Operating margin Operating income as a share of revenue.
20.2%
9.6 pts
Net income Profit after all expenses, interest and tax.
$234M
25.2%
Free cash flow Cash from operations minus capital spending.
$354M
28.2%
Return on capital After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
22.7%
24.5 pts
Market cap Last close times the latest diluted share count, so it is approximate.
$6.7B
Oct 23 close
P/E Last close divided by diluted earnings per share over the last four quarters.
24.2x
On $4.13 EPS (TTM)

What Lantheus does

No business description yet.

Legal name
Lantheus Holdings, Inc.
Fiscal year ends
December 31, 2025
Latest annual report
—
Accession · CIK
0001193125-26-073498
0001521036

Revenue and margins

Lantheus had $1.5B of revenue in fiscal 2025, up 0.5% on the year before.

Revenue
Revenue
Margins, % of revenue
Gross Operating Net FCF
Margins, % of revenue
Gross Operating Net FCF

Net income and earnings per share

From fiscal 2016 to 2025, diluted EPS grew 17.2% a year. Loss periods are shown in red.

Net income
Net income
Diluted EPS
Diluted EPS

Returns on capital

After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.

Return on capital, equity and assets (annual)
Return on capital Return on equity Return on assets

Cash flow

Free cash flow was $354M in fiscal 2025, 23.0% of revenue. Cash from operations minus capital spending.

Free cash flow
Free cash flow
Cash from operations vs capital spending
Cash from operations Capital spending
Cash from operations vs capital spending
Cash from operations Capital spending

Dividends, buybacks and share count

Lantheus returned $300M to shareholders in fiscal 2025, 85% of free cash flow. The diluted share count fell 4.5%.

Dividends and buybacks
Dividends Buybacks
Dividends and buybacks
Dividends Buybacks
Diluted shares outstanding (annual)

Value Lantheus yourself

Change the assumptions and see what they imply per share. These are models, not forecasts or price targets — the answer depends entirely on what you put in.

Discounted cash flow

Value per share

—

Adds net cash of −$210M and divides by 68.4M diluted shares. Ten years of cash flows plus a terminal value, discounted to today.

Earnings multiple

Value per share

—

Reference multiples: today 24.2x · peers 53.7x · sector 28.4x.

Balance sheet

Cash, debt and the ratios that show how comfortably Lantheus can carry it.

Cash vs debt (incl. leases)
Cash Debt
Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments $98.5M$416M$714M$913M$359M
Debt incl. finance leases $176M$559M$563M$566M$569M
Net debt / EBITDA —1.7x−0.4x−0.7x0.6x
Debt / equity 0.4x1.3x0.7x0.5x0.5x
Interest coverage −7.9x5.0x18.2x23.2x15.7x
Current ratio 2.6x2.7x5.8x5.5x2.7x
Quick ratio 2.2x2.6x5.5x5.2x2.5x
Total assets $864M$1.3B$1.7B$2.0B$2.2B
Total liabilities $399M$874M$835M$892M$1.1B
Shareholders' equity $464M$447M$816M$1.1B$1.1B
Net debt (− = net cash) $77.0M$143M−$151M−$347M$210M

Insider trades

Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. 'Plan' marks trades under a pre-arranged Rule 10b5-1 plan.

Bought, 12 months

$0.0M

0 insiders

Sold, 12 months

$0.0M

0 insiders

Of sales under plans

—

$0.0M

No open-market insider trades in the last 12 months.

Piotroski F-score

Nine pass/fail tests of profitability, funding and efficiency. 8–9 is strong, 0–2 weak.

TestFY23FY24FY25
Net income is positive ✓ ✓ ✓
Cash from operations is positive ✓ ✓ ✓
Return on assets rose ✓ ✕ ✕
Cash from operations exceeds net income ✕ ✓ ✓
Debt fell relative to assets ✓ ✓ ✓
Current ratio rose ✓ ✕ ✕
Share count didn't rise ✓ ✕ ✓
Gross margin rose ✕ ✓ ✕
Revenue rose relative to assets ✕ ✕ ✕
F-score 6 / 95 / 95 / 9
Accruals ratio 1.4%−12.8%−7.4%
Altman Z'' 6.347.164.61

Similar companies

Each company's latest fiscal year. Fiscal years end in different months, so periods don't line up exactly.

CompanyMarket capGrowthOp. marginFCF marginROICP/EF-score
Lantheus LNTH $6.7B 0.5% 20.2% 23.0% 22.7% 24.2x 5
Haemonetics HAE $5.4B −2.0% 11.8% 19.5% 6.7% 57.3x 7 Compare →
ICU Medical ICUI $4.2B −6.3% 1.9% 4.1% 0.7% 140.0x 6 Compare →
Envista NVST $3.9B 8.3% 8.0% 8.5% 3.2% 40.7x 7 Compare →
West Pharmaceutical Services WST $28.0B 6.3% 19.0% 15.3% 18.7% 50.2x 9 Compare →

10 years of figures

US$ millions unless stated. Hover a ratio's name for its definition.

Download CSV
Fiscal yearFY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue $302M $331M $343M $347M $339M $425M $935M $1.3B $1.5B $1.5B
Gross profit $138M $162M $175M $175M $139M $188M $582M $710M $988M $942M
Research and development $12.2M $18.1M $17.1M $20.0M $32.8M $45.0M $312M $77.7M $168M $177M
Operating income $56.6M $51.9M $64.5M $51.7M −$4.2M −$60.8M $36.2M $365M $457M $311M
Interest expense $26.6M $18.4M $17.4M $13.6M $9.5M $7.8M $7.2M $20.0M $19.7M $19.7M
Pretax income $28.3M $39.6M $49.5M $28.6M −$11.5M −$75.0M $26.7M $411M $431M $314M
Income tax $1.5M −$83.7M $9.0M −$3.0M $2.0M −$3.8M −$1.3M $84.3M $119M $80.2M
Net income $26.8M $123M $40.5M $31.7M −$13.5M −$71.3M $28.1M $327M $312M $234M
Diluted EPS $0.82 $3.17 $1.03 $0.79 −$0.25 −$1.06 $0.40 $4.65 $4.36 $3.41
Diluted shares 0.03B 0.04B 0.04B 0.04B 0.05B 0.07B 0.07B 0.07B 0.07B 0.07B
Cash flow
Cash from operations $49.6M $54.8M $61.2M $80.4M $16.4M $53.9M $282M $305M $545M $390M
Capital expenditure $7.4M $17.5M $20.1M $22.1M $0.0M $0.0M $260M $45.3M $51.6M $36.1M
Free cash flow $42.2M $37.2M $41.1M $58.3M $16.4M $53.9M $21.8M $260M $493M $354M
Depreciation and amortization $17.3M $18.2M $12.8M $12.1M $23.3M $42.3M $47.9M $60.0M $64.6M $70.1M
Stock-based compensation $2.5M $5.9M $8.7M $12.5M $14.1M $15.9M $29.3M $50.5M $76.4M $85.6M
Acquisitions $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M
Share buybacks $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $75.0M $0.0M $100M $300M
Dividends paid $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M
Dividends and buybacks $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $75.0M $0.0M $100M $300M
Balance sheet
Cash and short-term investments $51.2M $76.3M $113M $92.9M $79.6M $98.5M $416M $714M $913M $359M
Total debt $278M $268M $267M $194M $218M $175M $558M $563M $566M $569M
Finance lease liabilities $0.0M $0.0M $0.0M $0.3M $0.5M $0.7M $0.6M $1.4M $1.6M $1.2M
Current assets $111M $148M $195M $173M $184M $236M $678M $1.1B $1.3B $900M
Current liabilities $43.8M $46.8M $52.8M $66.1M $80.5M $90.5M $248M $187M $241M $333M
Inventory $17.6M $26.1M $33.0M $29.2M $35.7M $35.1M $35.5M $64.0M $68.0M $64.7M
Property and equipment, net $94.2M $93.0M $108M $117M $120M $117M $122M $147M $177M $164M
Total assets $256M $384M $440M $406M $870M $864M $1.3B $1.7B $2.0B $2.2B
Total liabilities $362M $361M $369M $291M $356M $399M $874M $835M $892M $1.1B
Shareholders' equity −$107M $23.3M $71.0M $115M $514M $464M $447M $816M $1.1B $1.1B
Margins
Gross margin 45.6% 48.9% 50.9% 50.3% 40.9% 44.1% 62.2% 54.7% 64.4% 61.1%
Operating margin 18.8% 15.7% 18.8% 14.9% −1.2% −14.3% 3.9% 28.1% 29.8% 20.2%
EBITDA margin 24.5% 21.1% 22.5% 18.4% 5.6% −4.4% 9.0% 32.8% 34.0% 24.7%
Net margin 8.9% 37.2% 11.8% 9.1% −4.0% −16.8% 3.0% 25.2% 20.4% 15.2%
FCF margin 14.0% 11.2% 12.0% 16.8% 4.8% 12.7% 2.3% 20.1% 32.2% 23.0%
Returns
Return on capital 41.2% 30.9% 24.0% 23.5% −0.8% −8.0% 6.4% 46.2% 47.1% 22.7%
Return on capital employed 27.0% 18.9% 17.8% 14.2% −0.7% −7.8% 3.9% 28.7% 28.5% 17.1%
Return on equity — — 85.9% 34.1% −4.3% −14.6% 6.2% 51.7% 32.8% 21.5%
Return on assets 10.7% 38.6% 9.8% 7.5% −2.1% −8.2% 2.6% 22.0% 17.2% 11.1%
Growth
Revenue growth 2.9% 9.8% 3.6% 1.2% −2.3% 25.3% 119.9% 38.7% 18.3% 0.5%
Net income growth — 361.1% −67.2% −21.8% −142.6% — — 1,063.9% −4.4% −25.3%
EPS growth — 286.6% −67.5% −23.3% −131.7% — — 1,062.5% −6.2% −21.8%
FCF growth 390.6% −11.9% 10.3% 42.0% −71.9% 228.8% −59.6% 1,093.3% 89.7% −28.2%
Share count change 33.6% 19.1% 1.6% 1.6% 35.0% 24.7% 4.7% −0.6% 2.0% −4.5%
Financial health
Net debt / EBITDA 3.1x 2.7x 2.0x 1.6x 7.3x — 1.7x −0.4x −0.7x 0.6x
Debt / equity — 11.5x 3.8x 1.7x 0.4x 0.4x 1.3x 0.7x 0.5x 0.5x
Interest coverage 2.1x 2.8x 3.7x 3.8x −0.4x −7.9x 5.0x 18.2x 23.2x 15.7x
Current ratio 2.5x 3.2x 3.7x 2.6x 2.3x 2.6x 2.7x 5.8x 5.5x 2.7x
Quick ratio 2.1x 2.6x 3.1x 2.2x 1.8x 2.2x 2.6x 5.5x 5.2x 2.5x
Capital allocation
Capex / revenue 2.5% 5.3% 5.9% 6.4% 0.0% 0.0% 27.8% 3.5% 3.4% 2.3%
Stock comp / revenue 0.8% 1.8% 2.5% 3.6% 4.2% 3.8% 3.1% 3.9% 5.0% 5.6%
Payouts / FCF 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 344.3% 0.0% 20.3% 84.7%
Quality scores
Piotroski F-score 6.0 7.0 6.0 4.0 4.0 5.0 7.0 6.0 5.0 5.0
Altman Z'' −1.3 0.9 2.1 1.9 1.7 1.0 2.4 6.3 7.2 4.6
Accruals ratio −9.2% 21.5% −5.0% −11.5% −4.7% −14.4% −23.2% 1.4% −12.8% −7.4%

Source: SEC EDGAR XBRL filings (CIK 0001521036). Data updated October 16, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only — not investment advice. Check the original filings before relying on any figure.

↑ ↓ to move · ↵ to open